Stock XFOR X4 PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Real-time Estimate Cboe BZX
Other stock markets
 11:50:10 2024-06-06 am EDT 		5-day change 1st Jan Change
1.035 USD -4.17% Intraday chart for X4 Pharmaceuticals, Inc. +6.57% +24.03%
May. 09 Sector Update: Health Care Stocks Higher Late Afternoon MT
May. 09 X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
AQ
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
AQ
X4 Pharmaceuticals: Q1 Earnings Snapshot
AQ
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
AQ
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K
PU
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
AQ
X4 Pharmaceuticals: Q4 Earnings Snapshot
AQ
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
AQ
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
AQ
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
PR
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XFOR Stock
  4. News X4 Pharmaceuticals, Inc.
  5. Press Releases